STAT Biotech

Recent stories from STAT Biotech.

STAT Biotech Meghana Keshavan

STAT+: Lawmakers want U.S. biotech to outcompete China

Lawmakers leading the congressional BIOTech Caucus say Washington needs to act in the sector — and fast:

Read at STAT Biotech

STAT Biotech Sarah Todd and Katie Palmer

STAT+: Peptide market poised to explode with new Hims and Noom launches

Two telehealth giants rolled out peptide programs this week after HHS made it easier for compounding pharmacies to offer drugs like BPC-157.

Read at STAT Biotech

STAT Biotech Katherine MacPhail

Merck, Isomorphic Labs partner to develop oncology drug candidates

Merck and Isomorphic Labs said they are entering into a research collaboration to discover small molecule candidates in oncology.

Read at STAT Biotech

STAT Biotech Adam Feuerstein

STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment

Did the biotech company Erasca find a more potent, better-tolerated pan-RAS cancer drug than Revolution Medicines?

Read at STAT Biotech

STAT Biotech Margaret Manto

STAT+: 7 burning questions about the FDA’s post-Overton future

STAT tackles the most important questions about the FDA's uncertain future.

Read at STAT Biotech

STAT Biotech Elaine Chen and Adam Feuerstein

STAT+: FDA discloses reasons for rejecting Summit drug

The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:

Read at STAT Biotech

STAT Biotech Elaine Chen

STAT+: Flagship opens biotech-creation outpost in the U.K.

Flagship is putting up 100 million pounds to start “AI-native platform companies" focused on human and planetary health in the U.K.:

Read at STAT Biotech

STAT Biotech Adam Feuerstein

STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial

Sellas' experimental blood cancer immunotherapy reduced the risk of death in clinical trial.

Read at STAT Biotech

STAT Biotech Jason Mast

STAT+: With $173 million, new startup takes aim at sickle cell

Researchers are seeking a sickle cell treatment as effective as gene therapy, without the drawbacks. This entrepreneur thinks he might have one.

Read at STAT Biotech

STAT Biotech Jason Mast

STAT+: After death in gene therapy trial for a brain disease, progress is reported

An unexpected patient death rattled researchers who sought to pierce the blood-brain barrier. Now some think they have a better way of mitigating risks.

Read at STAT Biotech

STAT Biotech Margaret Manto

STAT+: In a win for MAHA, FDA creates new regulatory category for the supplement NAC

The supplement NAC has been widely available for years, but exists in a legal gray area.

Read at STAT Biotech

STAT Biotech Meghana Keshavan

STAT+: Biotech’s rebound isn’t lifting all boats equally

Biotech is having a good year, though you wouldn't necessarily know it from how investors are treating positive clinical data.

Read at STAT Biotech

STAT Biotech Elaine Chen

STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions

A psychedelic drug from Helus Pharma improved depression in a study, but is facing safety questions with a number of serious adverse events reported.

Read at STAT Biotech

STAT Biotech Adam Feuerstein

STAT+: Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence

CG Oncology's bladder cancer immunotherapy reduced risk of tumor recurrence by 68% — results that may change how physicians treat certain patients.

Read at STAT Biotech

STAT Biotech Jason Mast

STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues

Versant Ventures, Eli Lilly, and a handful of other investors will pour $100 million into a new startup devoted to solving a thorny gene therapy challenge.

Read at STAT Biotech

STAT Biotech Damian Garde

BeOne, Hengrui top list of China’s most powerful drugmakers

A new STAT-WireScreen index ranks China's most valuable publicly traded biotech companies. See which one topped the list.

Read at STAT Biotech

STAT Biotech Adam Feuerstein

STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics

The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.

Read at STAT Biotech

STAT Biotech Meghana Keshavan

STAT+: HHS plans funding for research into ibogaine for PTSD

The Trump administration will funnel up to $4.9 million into supporting research into ibogaine, a psychedelic that’s drawn interest as a potential treatment for PTSD and addiction.

Read at STAT Biotech

STAT Biotech Elaine Chen

STAT+: Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say

With a new deal announced this week, the relationship between Eli Lilly and a telehealth company that markets GLP-1s is expected to grow more complicated.

Read at STAT Biotech

STAT Biotech Meghana Keshavan

STAT+: Blackstone backs Pfizer’s bet on monthly obesity treatment

Pfizer spent up to $10 billion to buy Metsera last year. Now, it’s bringing in private equity behemoth Blackstone to help pay for the deal.

Read at STAT Biotech

STAT Biotech Adam Feuerstein

STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem

Alnylam is heavily dependent on its heart drug Amvuttra for growth — and sales have been slowing.

Read at STAT Biotech

STAT Biotech Adam Feuerstein

STAT+: What to know about Biogen’s big lupus study readout

Biogen is expected to soon release the results of pivotal clinical trials of an experimental therapy for lupus.

Read at STAT Biotech

STAT Biotech Elaine Chen

STAT+: Most-favored nations policy makes drugmakers rethink launches abroad

Drug companies seem to be looking for workarounds to protect their U.S. sales against Trump's "most-favored nations" policy:

Read at STAT Biotech

STAT Biotech Elaine Chen

STAT+: GLP-1s are given an FDA warning for rare eye condition risk

The FDA warned that GLP-1 drugs carry a potential risk of a rare but serious eye condition sometimes referred to as an “eye stroke.”

Read at STAT Biotech

STAT Biotech Jason Mast

STAT+: PepGen says early trial for muscular dystrophy drug looks promising

PepGen says its candidate is correcting more of the genetic stutter found in myotonic dystrophy type 1.

Read at STAT Biotech

STAT Biotech Elaine Chen and Elizabeth Cooney

STAT+: FDA approves novel Bayer drug to reduce recurrence of stroke

Bayer's drug is the first in a novel class of medications designed to prevent blood clots without increasing risk of bleeding.

Read at STAT Biotech

STAT Biotech Elaine Chen

STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition

The FDA on Monday warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition that's sometimes referred to as an "eye stroke."

Read at STAT Biotech

STAT Biotech Meghana Keshavan and Brittany Trang

STAT+: Gene therapy’s long-debated cancer risk materializes

For years, gene therapy researchers debated whether the viruses they use to ferry replacement genes into cells could cause tumors. A small number of cases now offer strong evidence that…

Read at STAT Biotech

STAT Biotech Matthew Herper

STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype

Once again, a hot new technology that was supposed to speed up drug research has fallen flat.

Read at STAT Biotech

STAT Biotech John Wilkerson

STAT+: BIO joins the legal fight against Medicare pilot that ties drug prices to peer countries

The model is a test of Trump's most-favored nation approach to drug pricing, though its impact is likely to be limited.

Read at STAT Biotech

Older stories